Frequency of Cytomegalovirus Viral Load in Iranian Human Immunodeficiency Virus-1-Infected Patients with CD4+ Counts <100 Cells/mm³

Mohammad Reza Jabbari a Hoorieh Soleimanjahi a
Somayeh Shatizadeh Malekshahi a Mohammad Gholami b
Leila Sadeghi b Minoo Mohraz b

 aDepartment of Virology, Faculty of Medical Sciences, Tarbiat Modares University, Tehran, Iran; bIranian Institute for Reduction of High-Risk Behaviors, Iranian Research Center For HIV/AIDS, Tehran, Iran

Keywords
Cytomegalovirus infection · Human immunodeficiency virus-1 · Retinitis · Viral load · Epidemiology · Virology

Abstract
Objectives: The aim of present work was to assess cytomegalovirus (CMV) viremia in Iranian human immunodeficiency virus (HIV)-1-infected patients with a CD4+ count <100 cells/mm³ and to explore whether CMV DNA loads correlate with CD4+ cell counts or associated retinitis. Methods: This study was conducted at the AIDS research center in Iran on HIV-1-infected patients with CD4+ count <100 cells/mm³, antiretroviral therapy-naïve, aged ≥18 years with no previous history of CMV end-organ disease (CMV-EOD). Results: Thirty-nine of 82 patients (47.56%) had detectable CMV viral load ranging from 66 to 485,500 IU/mL. CMV viral load in patients with retinitis ranges from 352 to 2,720 IU/mL, and it was undetectable in 2 patients. No significant associations between CMV viremia and CD4+ cell count was found (p value = 0.31), whereas significant association of CMV viremia in HIV-infected patients with retinitis was found (p < 0.02). Conclusions: We estimated the frequency of CMV viral load infection in Iranian HIV-1-infected patients with a CD4+ cell count <100 mm³/mL in the largest national referral center for HIV-1 infection in Iran. Further research is required on the relevance of CMV viral load in diagnostic and prognostic value of CMV-EOD.

Introduction
Roughly 37 million people are infected with human immunodeficiency virus (HIV) globally [1]. Cytomegalovirus (CMV) is a ubiquitous human herpes virus with a prevalence rate of 60 and 95% in adult individuals in developed and developing countries, respectively [2, 3]. Primary CMV infection in immunocompetent people could be mild or subclinical, although primary CMV infection in immunocompromised individuals can produce diverse life-threatening end-organ diseases (EODs) [4]. The clinical presentations of CMV-EOD include CMV retinitis, pneumonitis, nephritis, encephalitis, esophagitis, hepatitis, colitis, myocarditis, and others [5]. Although antiretroviral therapy has dramatically reduced its incidence among HIV-infected patients [6, 7], CMV disease remains a threat in patients with immunodefi-
CMV disease typically occurs when the CD4+ cell count falls below 100 cells/mm³ in HIV-positive patients [9]. Thus, earlier diagnosis and pre-emptive treatment may help reduce the morbidity and mortality in these patients as seen in transplantation [10]. The goal of the present investigation was to assess CMV viremia in Iranian HIV-1-infected patients with CD4+ counts <100 cells/mm³ and to explore whether CMV DNA loads correlate with CD4+ cell counts or associated retinitis. To the best of our knowledge, this is the first demonstration of the frequency of CMV viral load in Iranian HIV-1-infected patients with CD4+ counts <100 cells/mm³.

### Materials and Methods

#### Study Design

This study was conducted at the AIDS research center in Imam Khomeini Hospital in Iran, affiliated to the Tehran University of Medical Sciences (TUMS) between April 2016 and April 2018. The study population comprised 82 HIV-1-infected patients with CD4+ counts <100 cells/mm³, antiretroviral therapy-naive (either being poor medication adherence or being new patients) aged ≥18 years, and patients with no previous history or evidence of CMV-EOD. The current study was approved by the Ethical Committee of Tarbiat Modares University (IR.TMU.REC.1394.308), and all patients who met the entry criteria signed an informed consent prior to the enrollment.

#### CMV Viremia Assay

Three milliliters of whole blood samples were mixed promptly with the EDTA from the eligible patients, and plasma DNA extraction was carried out using a DNA extraction kit (Invisorb Blood Universal Kit, stratec) according to manufacturers' instruction. Quantitative plasma CMV DNA PCR was measured using a GeneProof RT-PCR kit and run on the StepOne Real-Time PCR System. The assay had a lower detection limit of 0.907 copies DNA per µL. The PCR conditions were as follows: 10 min at 95°C, followed by 45 cycles of 5 s at 95°C, 40 s at 60°C, and 40 s at 60°C.

#### Statistical Analysis

Statistical analysis was performed using SPSS version 24 (IBM, Armonk, NY, USA). A \( p \) value <0.05 was considered significant. The Kolmogorov-Smirnov and independent \( t \) tests were used to assess the association of CMV viremia with the CD4+ cell count and retinitis, respectively.

### Results

#### Demographic Characteristics

The details of the basic demographic and laboratory data of the HIV-1-infected patients are shown in our previously published article [11]. In brief, among 82 HIV-1-infected patients, there were 67 (81.7%) male and 15 (18.29%) female, with a mean age of 38 ± 7 years. All of them had CD4+ cell counts of <100 cells/mm³, with a mean CD4+ cell count of 46.84 cells/mm³. The status of CMV IgG was as follows: 71 (86.5%) patients were positive, 2 (2.4%) patients were negative, and 9 (10.9%) patients were undetermined.

#### Table 1. Characteristics of 39 patients with detectable CMV viral load

| Patient, n | Sex | Age, years | CD4+ cell count, cells/mm³ | CMV-EOD | CMV viral load, IU/mL |
|-----------|-----|------------|-----------------------------|---------|-----------------------|
| 1         | Male | 34         | 48                          | –       | 1,240                 |
| 2         | Male | 41         | 53                          | –       | 580                   |
| 3         | Male | 33         | 20                          | –       | 940                   |
| 4         | Male | 33         | 72                          | Encephalitis | 72      |
| 5         | Male | 35         | 32                          | –       | 2,480                 |
| 6         | Male | 43         | 23                          | –       | 190                   |
| 7         | Male | 30         | 38                          | Retinitis | 1,480    |
| 8         | Male | 57         | 60                          | –       | 720                   |
| 9         | Male | 28         | 66                          | –       | 110                   |
| 10        | Male | 52         | 47                          | Retinitis | 2,720   |
| 11        | Male | 44         | 40                          | –       | 875                   |
| 12        | Male | 35         | 18                          | Colitis  | 970                  |
| 13        | Female | 30      | 39                          | –       | 654                   |
| 14        | Male | 44         | 43                          | –       | 350                   |
| 15        | Male | 36         | 51                          | Retinitis | 740     |
| 16        | Male | 34         | 38                          | –       | 556                   |
| 17        | Male | 38         | 5                           | –       | 420                   |
| 18        | Female | 47     | 25                          | Colitis  | 485,500              |
| 19        | Male | 41         | 74                          | –       | 235                   |
| 20        | Male | 34         | 81                          | –       | 1,140                 |
| 21        | Male | 34         | 46                          | Retinitis | 352     |
| 22        | Male | 48         | 19                          | –       | 565                   |
| 23        | Male | 45         | 37                          | –       | 573                   |
| 24        | Male | 39         | 41                          | –       | 430                   |
| 25        | Male | 39         | 10                          | Retinitis | 872     |
| 26        | Male | 36         | 54                          | –       | 680                   |
| 27        | Male | 47         | 68                          | –       | 920                   |
| 28        | Female | 40    | 33                          | Retinitis | 1,052   |
| 29        | Male | 48         | 46                          | –       | 85                    |
| 30        | Male | 44         | 54                          | –       | 235                   |
| 31        | Male | 42         | 16                          | –       | 560                   |
| 32        | Male | 31         | 54                          | Retinitis | 650     |
| 33        | Male | 45         | 47                          | –       | 724                   |
| 34        | Male | 29         | 62                          | Colitis  | 66                    |
| 35        | Male | 41         | 77                          | –       | 475                   |
| 36        | Male | 38         | 8                           | –       | 126                   |
| 37        | Male | 44         | 48                          | Encephalitis | 530   |
| 38        | Male | 40         | 73                          | –       | 615                   |
| 39        | Male | 35         | 64                          | –       | 374                   |

CMV, cytomegalovirus; EOD, end-organ disease.
CMV Viral Load, CD4+ Cell Count, and CMV-EOD

Table 1 shows the quantities of CMV viral load, age, sex, CD4+ cell count, and CMV-EOD in 39 patients with detectable CMV viral load.

CMV Viremia Status

Of the 82 plasma samples tested for CMV viremia, 39 patients (47.56%) had detectable viral load ranging from 66 to 485,500 IU/mL. Table 2 demonstrates the characteristics of patients with retinitis and their quantity of CMV DNA. CMV viral load in patients with retinitis ranges from 352 to 2,720 IU/mL, and it was undetectable in 2 patients. No significant associations between CMV viremia and CD4+ cell count were found (p value = 0.31), whereas a significant association of CMV viremia in HIV-infected patients with retinitis was found (p < 0.02).

Discussion

Our study of 82 HIV-infected patients with CD4+ counts <100 cells/mm³ who were screened concomitantly for the presence of CMV viremia showed that the overall prevalence of retinitis in this population was 10.9% at 1 year. CMV retinitis is a common and relatively late manifestation of HIV-associated ocular disease [12]. A systematic review of HIV-related CMV retinitis in resource-limited settings found that the prevalence of CMV retinitis remains high, especially in Asian countries with a pooled prevalence of 14% [13]. In fact, compared to surveys conducted in South Africa (2.6%) [14], Tanzania (1.3%) [15], Nigeria (1.2%) [16], and Malawi (4.9%) [17], much higher levels of HIV-related CMV retinitis in Asian populations such as Shanghai, China (7.6%) [18], South Korea (11%) [19], Thailand (19.8%) [20], and Myanmar (24%) [21] were reported. Early screening of CMV retinitis among patients with CD4+ counts <100 cells/mm³ is an important issue for preventing vision loss, but it is rarely done in practice [22]. In Abdollahi et al.’s [23] study, the prevalence of CMV retinitis in Iranian HIV-1-infected patients with CD4+ counts 143 ± 84 cells/µL was reported 1.88%. It could be assumed that the main difference between the latter and the current study is considered to be in the CD4+ cell count. This is in line with the findings that a CD4+ cell count less than 100 cells/µL is associated with ophthalmic manifestations, as shown by Lai et al. [24] with a mean CD4+ count of 85.9 cells/µL and Gharai et al. [25] with a median CD4+ count of 75 cells/mm.

The current study is the first demonstration of the frequency of CMV viral load in Iranian HIV-1-infected patients with CD4+ counts <100 cells/mm³. It helps increase the data on the association between CMV viremia and CD4+ cell count. In the present study, CMV viremia was found in the approximately half of the patients (47.56%) over a period of 1 year with a range of 66–485,500 IU/mL. From a limited number of published data in developing countries, the prevalence of CMV viremia in HIV-infected patients was reported to be 42.4% in Cambodia [26], 5.2% in South Africa [27], and 26.3% in Thailand [5]. A number of studies have shown that patients with detectable levels of CMV DNA in the blood and CD4+ T-cell counts <100 cells/µL may be at increased risk of developing CMV diseases [28–30]. For example, the results of a recent study conducted by Tang et al. [30] showed that HIV-infected patients with CD4 cell counts <50/µL along with a CMV DNA level >2,000 copies/µL are at higher risk of developing CMV retinitis. Accordingly, in our previous study, 14 patients were diagnosed with CMV-EOD, in whom retinitis occurred in the greatest number of patients (64.28%), followed by colitis (21.42%) and encephalitis (14.28%) [11]. However, there was an unusual finding in our study that CMV DNA was undetectable in 2 patients with retinitis. Likewise, in El Amari et al.’s [31] study, CMV DNA was undetectable in 17% of the patients who developed CMV-EOD. In this regard, they argued about the delay between CMV DNA measurement and the occurrence of the disease (median 141 days). Another study pointed out about the transient occurrence of CMV viremia and missing its detection due to intermittent

| Patient, n | Age, years | Sex | CD4+ cell count, cells/mm³ | CMV-EOD | CMV viral load, IU/mL |
|------------|------------|-----|---------------------------|---------|----------------------|
| 1          | 52         | Male | 47                         | Retinitis | 2,720               |
| 2          | 30         | Male | 38                         | Retinitis | 1,480               |
| 3          | 41         | Male | 53                         | Retinitis |                     |
| 4          | 36         | Male | 51                         | Retinitis | 740                 |
| 5          | 34         | Male | 46                         | Retinitis | 352                 |
| 6          | 39         | Male | 10                         | Retinitis | 872                 |
| 7          | 40         | Female | 33                       | Retinitis | 1,052               |
| 8          | 31         | Male | 54                         | Retinitis | 650                 |
| 9          | 44         | Male | 49                         | Retinitis |                     |

CMV, cytomegalovirus; EOD, end-organ disease; HIV, human immunodeficiency virus.
sampling [32]. Further studies observing more cases are needed to explore the reason of this issue. Moreover, our results did not support the association between CMV viremia and the CD4+ cell count (p-value = 0.31). It means that the presence of CMV in the blood is independent of the CD4+ cell count. However, there was a significant association between CMV viremia and retinitis. The results of studies by Erice et al. [33] and Wohl et al. [34] showed that the predictors of CMV-EOD disease include detectable CMV DNA with a viral load greater than 200 copies/μL. In contrast, Wiselka et al. [35] reported that CMV viremia had a poor predictive value for subsequent CMV disease in a cohort of patients with advanced HIV infection. Other than the predictive value, the high diagnostic value of CMV viremia for the diagnosis of CMV-EOD has been demonstrated in some studies [36, 37]. However, further research is required on the relevance of CMV viral load in diagnostic and prognostic value of CMV-EOD [33].

In this study, we tried to investigate the effect and importance of CMV existence as an important cofactor in HIV disease, with an influence on clinical outcome. We estimated the frequency of CMV viral load infection in Iranian HIV-1-infected patients with CD4+ cell counts less than 100 mm3/mL in the largest national referral center for HIV-1 infection in Iran. Our data contribute to the significant association between CMV viremia and retinitis. But, the presence of CMV in the blood was independent of the CD4+ cell count. Based on the present finding, one can say that when the CMV viral load is >352 IU/mL in HIV-1-infected patients, ophthalmic examination is endorsed, which can be helpful for patients’ management. Due to the relatively small sample size, further research in larger multicenter clinics is required on the relevance of CMV viral load in diagnostic and prognostic value of CMV-EOD in order to verify these findings.

**Statement of Ethics**

The current study was approved by the Ethical Committee of Tarbiat Modares University (IR.TMU.REC.1394.308).

**Conflict of Interest Statement**

The authors have no conflicts of interest to declare.

**Funding Sources**

This study was performed as a PhD project (grant No. 1248983) supported financially by Tarbiat Modares University.

**Author Contributions**

Hoorieh Soleimanjahi designed the study and is the corresponding author. Mohammad Reza Jabbari participated in sample collection and carried out the laboratory experiments. Somayeh Shatizadeh Malekshahi wrote the manuscript. Moham mad Gholami and Leila Sadeghi coworked on RT-PCR experiments. Minoo Mohraz carried out patients’ recruitment and made diagnostic evaluations. All authors read and approved the final manuscript.

**References**

1. UNAIDS FS. Global statistics. 2015.
2. Mayaphi SH, Brauer M, Morobadi DM, Mazanderani AH, Mafayeku RT, Olorunju SA, et al. Cytomegalovirus viral load kinetics in patients with HIV/AIDS admitted to a medical intensive care unit: a case for pre-emptive therapy. PLoS One. 2014;9(4):e93702.
3. Munawwar A, Singh S. Human herpesviruses as copathogens of HIV infection, their role in HIV transmission, and disease progression. J Lab Physicians. 2016;8(1):5–18.
4. Tsai HP, Tsai YY, Lin IT, Kuo PH, Chen TY, Chang KC, et al. Comparison of two commercial automated nucleic acid extraction and integrated quantitation real-time PCR platforms for the detection of cytomegalovirus in plasma. PLoS One. 2016;11(8):e0160493.
5. Durier N, Ananworanich J, Apornpong T, Ubolam S, Korr S, Mahanontharit A, et al. Cytomegalovirus viremia in Thai HIV-infected patients on antiretroviral therapy: prevalence and associated mortality. Clin Infect Dis. 2013;57(1):47–55.
6. Salzberger B, Hartmann P, Hanses F, Uyanik B, Cornely OA, Wohrmann A, et al. Incidence and prognosis of CMV disease in HIV-infected patients before and after introduction of combination antiretroviral therapy. Infection. 2005;33(5–6):345–9.
7. Sugar EA, Jabs DA, Ahuja A, Thorne JE, Danis RP, Meinert CL. Studies of the ocular complications of AIDS research group. Incidence and prognosis of CMV disease in HIV-infected patients before and after introduction of combination antiretroviral therapy. J Clin Virol. 2006;37(1):1–9.
8. Jabs DA, Van Natta ML, Holbrook JT, Kempen IH, Meinert CL, Davis MD. Studies of the ocular complications of AIDS research group. Longitudinal study of the ocular complications of AIDS: 1. Ocular diagnoses at enrollment. Ophthalmology. 2007;114:780–6 e3.
9. Steininger C, Puchhammer-Stöckl E, Popow-Kraupp T. Cytomegalovirus disease in the era of highly active antiretroviral therapy (HAART). J Clin Virol. 2006;37(1):1–9.
10. Khansarinejad B, Soleimanjahi H, Mirab Samiee S, Hamidieh AA, Paryan M, Sanahmadi Y, et al. Monitoring human cytomegalovirus infection in pediatric hematopoietic stem cell transplant recipients: using an affordable house qPCR assay for management of HCMV infection under limited resources. Transpl Int. 2015;28:594–603.
11 Jabbari MR, Soleimanjahi H, Hajiabdolbaghi M, Sarraf-Shirazi M, Shatizadeh Malekshahi S. Cytomegalovirus end organ disease in Iranian HIV-1-infected patients with CD4 cell counts less than 100 Cells/mm3. Iran Red Crescent Med J. 2019;e95288.

12 Teoh SC, Wang PX, Wong EP. The epidemiology and incidence of cytomegalovirus retinitis in the HIV population in Singapore over 6 years. Invest Ophthalmol Vis Sci. 2012; 53(12):7546–52.

13 Ford N, Shubber Z, Saranchuk P, Pathai S, Durier N, O’Brien DP, et al. Burden of HIV-related cytomegalovirus retinitis in resource-limited settings: a systematic review. Clin Infect Dis. 2013;57(9):1351–61.

14 Pathai S, Gilbert C, Weiss HA, McNally M, Lawn SD. Differing spectrum of HIV-associated ophthalmic disease among patients starting antiretroviral therapy in India and South Africa. Trop Med Int Health. 2011;16(3):356–9.

15 Nirwoth JP, Hall AB, Lewallen S. Prevalence of cytomegalovirus retinitis in Tanzanians with low CD4 levels. Br J Ophthalmol. 2011;95(4):660–2.

16 Adeiza M, Habib AG. A cross-sectional study of cytomegalovirus retinitis in HIV-1 infected adults in Nigeria. Niger J Clin Pract. 2019;22(3):293–7.

17 Ocieczek P, Barnacle JR, Gumulira J, Phiri S, Heller T, Grabska-Liberek I. Cytomegalovirus retinitis screening and treatment in human immunodeficiency virus patients in Malawi: a feasibility study. Open Forum Infect Dis. 2019;6(11):ofz439.

18 Shi Y, Lu H, He T, Yang Y, Liu L, Zhang R, et al. Prevalence and clinical management of cytomegalovirus retinitis in AIDS patients in Shanghai, China. BMC Infect Dis. 2011;11:326.

19 Kim SJ, Park SJ, Yu HG, Kim NJ, Jang HC, Oh MD. Ocular manifestations of acquired immunodeficiency syndrome in Korea. J Korean Med Sci. 2012;27(5):542–6.

20 Manosuthi W, Chaovanavich A, Tanusphas-wadikul S, Prasitisirikul W, Inthong Y, Chatanapund S, et al. Incidence and risk factors of major opportunistic infections after initiation of antiretroviral therapy among advanced HIV-infected patients in a resource-limited setting. J Infect. 2007;55(5):464–9.

21 Tun N, London N, Kyaw MK, Smithuis F, Ford N, Margolis T, et al. CMV retinitis screening and treatment in a resource-poor setting: three-year experience from a primary care HIV/AIDS programme in Myanmar. J Int AIDS Soc. 2011;14:41.

22 Ausayakhun S, Yen M, Jirawison C, Ausayakhun S, Khunsongkiet P, Leenasirirakul P, et al. Visual acuity outcomes in cytomegalovirus retinitis: early versus late diagnosis. Br J Ophthalmol. 2018;102(12):1607–10.

23 Abdollahi A, Mohraz M, Rasoulinejad M, Shariati M, Kheirandish P, Abdollahi M, et al. Retinitis due to opportunistic infections in Iranian HIV infected patients. Acta Med Iran. 2013;51(10):711–14.

24 Lai TY, Wong RL, Luk FO, Chow VW, Chan CK, Lam DS. Ophthalmic manifestations and risk factors for mortality of HIV patients in the post-highly active anti-retroviral therapy era. Clin Experiment Ophthalmal. 2011;39(2):99–104.

25 Gharai S,Venkatesh P, Garg S, Sharma SK, Vohra R. Ophthalmic manifestations of HIV infections in India in the era of HAART: analysis of 100 consecutive patients evaluated at a tertiary eye care center in India. Ophthalmic Epidemiol. 2008;15(4):264–71.

26 Micol R, Buchy P, Guerrer G, Duong V, Ferradini L, Douset JP, et al. Prevalence, risk factors, and impact on outcome of cytomegalovirus replication in serum of Cambodian HIV-infected patients (2004–2007). J Acquir Immune Defic Syndr. 2009;51:486–91.

27 Fielding K, Koba A, Grant AD, Charalambos S, Day J, Spak C, et al. Cytomegalovirus viremia as a risk factor for mortality prior to antiretroviral therapy among HIV-infected gold miners in South Africa. PLoS One. 2011;6(10):e25571.

28 Rasmussen L, Morris S, Zipeto D, Fessel J, Wolitz R, Dowling A, et al. Quantitation of human cytomegalovirus DNA from peripheral blood cells of human immunodeficiency virus-infected patients could predict cytomegalovirus retinitis. J Infect Dis. 1995;171(1):177–82.

29 Spector SA, Wong R, Hsia K, Pilcher M, Stempien MJ. Plasma cytomegalovirus (CMV) DNA load predicts CMV disease and survival in AIDS patients. J Clin Invest. 1998;101(2):497–502.

30 Tang Y, Sun J, He T, Shen Y, Liu L, Steinhart CR, et al. Clinical features of cytomegalovirus retinitis in HIV infected patients. Front Cell Infect Microbiol. 2020;10:136–42.

31 El Amari EB, Combsbure C, Yerly S, Calmy A, Kaiser L, Hasse B, et al. Clinical relevance of cytomegalovirus viremia(*,†). HIV Med. 2011;12(7):394–402.

32 Wohl DA, Kendall MA, Andersen I, Crumpacker C, Spector SA, Feinberg I, et al. Low rate of CMV end-organ disease in HIV-infected patients despite low CD4+ cell counts and CMV viremia: results of ACTG protocol A5030. HIV Clin Trials. 2009;10:143–52.

33 Erice A, Tierney C, Hirsch M, Caliendo AM, Weinberg A, Kendall MA, et al. Cytomegalovirus (CMV) and human immunodeficiency virus (HIV) burden, CMV end-organ disease, and survival in subjects with advanced HIV infection (AIDS Clinical Trials Group Protocol 360). Clin Infect Dis. 2003;37:567–78.

34 Wohl DA, Zeng D, Stewart P, Gomb N, Alcorn T, Jones S, et al. Cytomegalovirus viremia, mortality, and end-organ disease among patients with AIDS receiving potent antiretroviral therapies. J Acquir Immune Defic Syndr. 2005;38(5):538–44.

35 Wiselka MJ, Nicholson KG, Rowley S, Bibby K. Cytomegalovirus viremia has poor predictive value for the development of cytomegalovirus disease in advanced HIV infected patients with advanced HIV infection. J Infect. 1999;39(3):187–92.

36 Pellegrin I, Garrigue I, Binquet C, Chene G, Neau D, Bonot P, et al. Evaluation of new quantitative assays for diagnosis and monitoring of cytomegalovirus disease in human immunodeficiency virus-positive patients. J Clin Microbiol. 1999;37(10):3124–32.

37 Yoshida A, Hitomi S, Fukui T, Endo H, Morisawa Y, Kazuyama Y, et al. Diagnosis and monitoring of human cytomegalovirus diseases in patients with human immunodeficiency virus infection by use of a real-time PCR assay. Clin Infect Dis. 2001;33(10):1756–61.